• Developing and Acquiring Innovative Artificial Intelligence Platforms.

• Advancing Next-Generation AI Systems, Including Automated Video Generation, Enterprise Documentation and Workflow Automation Solutions.

• Also Expanding Intellectual Property Portfolio in Cellular Therapy and Generative AI Publishing & Software.

• Marketing Breathalyzer Registered with U.S. Food and Drug Administration as a Class I Medical Device with Plans to Pursue Additional Diagnostic Applications.

• Agreement for Up to $9.75 Million Private Placement Priced At-the-Market.

• Accepted into AMD AI Developer Program to Advance Next-Generation Media Infrastructure.

• AMD Developer Cloud Expected to Accelerate High-Performance AI Video Generation, and Future Enterprise Automation and Scalable Deployment.

• Filed Third U.S. Provisional Patent for its Catch-Up Generative AI Video Platform.

• Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual Integrity.

• Majority of Debentures Eliminated Through $2.6 Million Conversion, Strengthening Balance Sheet and Reducing Overhang.

• AI Patent on Compliance-Ready Automated Video Commentary Covers Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos.

Avalon GloboCare Corp. (Nasdaq: ALBT) is a technology-focused company developing and acquiring innovative artificial intelligence platforms. Through its AI-driven subsidiary, Avalon Quantum AI LLC, ALBT is advancing next-generation AI systems, including automated video generation, enterprise documentation, and workflow automation solutions. ALBT is also expanding its intellectual property portfolio in cellular therapy and generative AI publishing and software.

In addition, ALBT is marketing the KetoAir™ breathalyzer device and plans to pursue additional diagnostic applications for the technology. The ALBT KetoAir™ is a handheld breathalyzer designed for ketogenic health management and is registered with the U.S. Food and Drug Administration under registration number 3026284320. The ALBT device measures breath acetone concentration (BrAce), a key biomarker associated with fat metabolism and nutritional ketosis. Leveraging advanced nano-sensor technology, KetoAir™ provides users with real-time, non-invasive insights into metabolic state through breath analysis. The ALBT KetoAir™ device is intended for individuals pursuing ketogenic diets for weight management, athletic performance, and therapeutic or lifestyle-based ketogenic programs. KetoAir™ is compatible with both iOS and Android smartphones, with companion applications available through the Apple App Store and Google Play Store.

ALBT plans to launch KetoAir™ in both business-to-business (B2B) and business-to-consumer (B2C) markets via Catch-Up™, an automated generative AI-powered software-as-a-service (SaaS) platform for creating short-form video content.

Up to $9.75 Million Private Placement Priced At-the-Market

On February 26th ALBT announced it has entered into agreements for the issuance and sale of 6,372,550 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share (or pre-funded warrant in lieu thereof) and associated warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $0.51 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. This agreement can deliver up to $9.75 Million to ALBT priced at-the-market including $3.25 million upfront with up to approximately $6.5 million of potential aggregate proceeds upon the exercise in full of warrants.

ALBT Subsidiary Accepted into Advanced Micro Devices ($AMD) AI Developer Program to Advance Next-Generation Media Infrastructure

Also on February 26th ALBT announced that it has been accepted into the Advanced Micro Devices (“AMD”) AI Developer Program, providing the Company with access to AMD Developer Cloud credits, advanced tools, training, and community resources designed to support and accelerate artificial intelligence development.

ALBT intends to leverage these resources primarily through its AI-driven subsidiary, Avalon Quantum AI LLC (“AQAI”), as the Company continues scaling its automated commentary video generation systems, and future planned enterprise documentation tools, and AI-powered workflow automation platform.

Participation in the AMD AI Developer Program provides ALBT with access to high-performance compute resources powered by AMD Instinct™️ accelerators and EPYC™️ processors via AMD Developer Cloud. These capabilities are expected to enhance model training efficiency, inference speed, and scalability of large language and multimodal AI systems powering AQAI’s platform.

ALBT AQAI is focused on developing AI systems capable of:

Automated, evidence-constrained commentary video generation.

AI-assisted drafting for public company communications.

Enterprise-grade compliance and workflow automation.

Adaptive content generation tailored to audience-specific requirements.

Third U.S. Provisional Patent for its Catch-Up Generative AI Video Platform

On February 18th ALBT announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligence–driven system designed to generate multiple personalized commentary video variants from a shared evidence framework while preserving factual integrity.

The provisional ALBT patent application, titled “Systems and Methods for Audience-Adaptive Generation of Evidence-Preserving Commentary Video Variants” (U.S. Provisional Patent Application No. 63/961,892), addresses a limitation in automated content systems, which traditionally distribute uniform commentary across diverse audiences or optimize for engagement at the expense of factual consistency. This ALBT technology is intended to generate multiple versions of the same commentary from a single verified evidence framework, allowing content to be tailored to different audience segments without altering the underlying facts.

The ALBT system is designed to analyze audience engagement data, topic preferences, and viewer characteristics to develop audience profiles. From a shared evidence structure, the ALBT platform aims to generate customized video variants that may differ in structure, emphasis, tone, pacing, and presentation style, while remaining bound by predefined evidence rules with the goal of ensuring factual consistency across all outputs.

Performance data from each distributed version is continuously collected and used to refine future content strategies. The ALBT platform is intended to also adapt content for short-form and long-form formats and align with regional, regulatory, and brand-specific requirements. Potential applications include personalized financial commentary, sports highlight recaps, and brand-safe marketing content optimized for individual audience segments and distribution channels.

Elimination of Majority of Debentures Through $2.6 Million Conversion, Strengthening Balance Sheet and Reducing Overhang

On February 2nd ALBT announced the conversion of the majority of its outstanding debentures, significantly strengthening the Company’s balance sheet.

The debentures originated from a June 2024 institutional investor convertible note financing with an aggregate principal amount of $2.8 million. Of this amount, $288 thousand of principal was repaid in cash, while the remaining $2.6 million of principal was converted into shares of ALBT common stock in accordance with the terms of the debentures, eliminating the majority of Avalon’s outstanding debt. ALBT believes that substantially all of the converted shares have been sold. ALBT also believes the debenture conversion removes a significant balance-sheet overhang, improves financial transparency, and supports long-term shareholder value creation.

AI Patent Targeting Compliance-Ready Automated Video Commentary

On January 22nd ALBT announced that its subsidiary, Avalon Quantum AI LLC, has filed a U.S. provisional patent application covering a new class of evidence-constrained generative AI systems designed to produce automated video commentary with built-in source traceability and auditability.

The ALBT provisional patent application, titled “Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos” (U.S. Provisional Patent Application No. 63/961,889) describes a proprietary AI architecture intended to address a structural risks in generative media markets: the inability to reliably verify, audit, and defend AI-generated outputs at scale. Unlike conventional generative video systems, the disclosed technology enforces an evidence-linked generation framework in which every narrative assertion within a rendered video must be explicitly supported by underlying source materials.

For more information on ALBT visit: www.avalon-globocare.com

Email: avco@crescendo-ir.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Avalon GloboCare Corp. (Nasdaq: ALBT)
Contact Person: Crescendo Communications, LLC, Investor Relations
Email: Send Email
Phone: (212) 671-1020 Ext. 304
Address:4400 Route 9 South Suite 3100
City: Freehold
State: NJ 07728
Country: United States
Website: www.avalon-globocare.com